A pan‐European collaboration cryed e ETERNAL project is set tae transform pharmaceutical manufacturin by reducin its environmental fitprint throu sustainable chemical an physical processes. E initiative, fit brings thegither saxteen pairtners fae industry, academia, an research institutes, emphasises fu life cycle approaches—fae drug design an manufactur tae product disposal—for tae minimise pollution, resoorce depletion, an greenhoose gas emissions.

E pharmaceutical industry faces growin scrutiny ower its contribution tae environmental degradation throu complex chemical syntheses, resoorce-intensive production, an waste generation. ETERNAL sikks tae address iss challenges by incorporatin green chemistry principles, mechanochemistry, an digitalisation tae optimize process performance an safety. E project’s framewark focuses on reducin solvent eese, enhancin resoorce recovery, an acceleratin process optimisation fyle ensurin compliance wi evolvin environmental regulations.

Quotient Sciences, a key pairtner in e consortium, is leveragin its expertise in digitalisation as pairt o the ETERNAL project. Their wark includes developin Digital Twins tae simulate an optimize processes. Thae digital representations aim tae reduce laboratory experimentation by allouin virtual experiments aat consume fewer reagents an solvents. As stated in e project documents, Quotient Sciences “aims tae reduce the nummer o experiments required at e laboratory or pilot scale, thereby minimisin resoorce consumption an waste generation.” Their approach nae ainly streamlines e scale-up o active pharmaceutical ingredient synthesis but provides real-time monitorin, reducin e risk o deviations an waste.

E Digital Twin technology developed by Quotient Sciences is a central component o the project’s strategy tae improve process efficiency an environmental performance. By enablin a reduction in physical experiments, e technology supports a mair sustainable approach tae drug development an manufacture. Iss innovation is reflective o the braider industry move tae integrated solutions aat prioritise baith environmental an economic benefits. E decreasin need for extensive lab-scale experimentation his e potential tae significantly cut emissions an reduce the eese o hazardous chemicals.

E ETERNAL project addresses hazardous waste management, e environmental risks associated wi active pharmaceutical ingredients, an e adoption o a circular economy model in manufacturin. E initiative encourages e eese o renewable feedstocks, energy-efficient processes, an real-time analysis an monitorin for tae foster safer, mair efficient operations.

As regulatory demands increase an societal expectations for environmental responsibility intensify, e collaborative efforts ithin ETERNAL unnerline a industry-wide commitment tae achieve sustainable pharmaceutical manufacturin. E project’s integrated approach micht serve as a blaeprint for ither global companies sikkin tae reduce their environmental impact fyle haudin heich product quality an operational efficiency.